Initial experience with point-of-care anti-CD19 CAR-T cells reveals safety and effectiveness in autoimmune disorders, suggesting a new treatment avenue.
Key Points
To evaluate the safety and clinical efficacy of point-of-care anti-CD19 CAR-T therapy in patients with severe autoimmune diseases.
Twelve patients with B-cell-driven autoimmune diseases received point-of-care anti-CD19 CAR-T cells, with varying dosages based on safety.
Primary endpoint focused on safety, particularly cytokine release syndrome and neurotoxicity.
Secondary endpoints included clinical responses, biomarker reductions, and CAR-T cell expansion.
Significant clinical improvements in three rheumatoid arthritis patients, with two becoming treatment-free.
Four of six systemic sclerosis patients saw reductions in modified Rodnan Skin Score, indicating improved skin condition.
The myasthenia gravis patient experienced significant neurological recovery and reduced MG-ADL score.